Skip to content

Bio-Rad Laboratories

US · BIO #1479 by market cap Listed 1970
367.92 -0.91 -0.25%
Live - 5344 symbols - heartbeat 435s ago · 2026-10-07 19:54
After-hours 367.12 -0.22%
Market cap
9.84B
P/B
1.37
EPS
27.85
Reader sentiment Are you bullish or bearish on BIO?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Clear Street Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $38
    Market Newswire · 2026/9/29
  • Rating change
    Wedbush Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/9/29
  • H.C. Wainwright Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/10/5
  • RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $390
    Market Newswire · 2026/9/28
  • Rating change
    CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/9/29
  • Rating change
    H.C. Wainwright Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/10/1
  • Rating change
    Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2
    Market Newswire · 2026/9/30
  • Rating change
    Stifel Maintains Braveheart Bio(BRVE.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/10/1
  • Company notice
    Huaheng Bio: Implementation and Assessment Management Measures for the 2026 Restricted Stock Incentive Plan of Anhui Huaheng Biotechnology Co., Ltd.
    SZSI · 2026/9/30
  • Citi Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/10/2
  • Rating change
    Clear Street Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/10/1
  • Rating change
    Citi Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $12
    Market Newswire · 2026/9/30
  • Company notice
    Climb Bio | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.
    SEC · 2026/10/1
  • Company notice
    Shengda Bio: Announcement on the Establishment of a Dedicated Settlement Account for Cash Management of Raised Funds and Progress in Utilizing Idle Raised Funds for Cash Management by Zhejiang Shengda Bio‑Pharmaceutical Co., Ltd.
    SZSI · 2026/10/1
  • Company notice
    Chengda Bio: Materials for the Second Extraordinary Shareholders' Meeting of Liaoning Chengda Bio Co., Ltd. for 2026
    SZSI · 2026/10/1
  • Company notice
    L&C BIO Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major Shareholders
    OPENDART · 2026/9/30
  • Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $59
    Market Newswire · 2026/10/1
  • Jefferies Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/10/1
  • Rating change
    H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/9/30
  • Rating change
    BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2026/10/2

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.